The state of North Carolina currently has 9 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
02/15/2024
Locations: Research Site, Gastonia, North Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
02/01/2024
Locations: Research Site, Charlotte, North Carolina +3 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
01/31/2024
Locations: Research Carolina Elite, Denver, North Carolina +3 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
Recruiting
This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
01/26/2024
Locations: Research Site, Gastonia, North Carolina +2 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Hypertension SOLAR
Recruiting
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
A Study of Patients With Chronic Disease
Recruiting
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.
Gender:
All
Ages:
All
Trial Updated:
08/24/2023
Locations: Coastal Carolina Healthcare, P.A., New Bern, North Carolina
Conditions: Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
SPIROMICS Study of Early COPD Progression (SOURCE)
Recruiting
This is an observational study of 600 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: To use CT scan imaging to identify which smokers will develop COPD. To identify biomarkers predictive of smokers that will develop COPD. To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related que... Read More
Gender:
All
Ages:
Between 30 years and 55 years
Trial Updated:
04/12/2023
Locations: Wake Forest, Winston-Salem, North Carolina
Conditions: COPD, Early-Onset
Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)
Recruiting
This study will determine the functional status of the nasal immune environment with LAIV exposure in COPD persons with frequent exacerbations (defined as individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months) and COPD persons without frequent exacerbations to determine acute exacerbation of COPD (AECOPD)-associated dysfunction in a) cytokines and immune effector cells of the nasal mucosa and b) viral repli... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2023
Locations: Eastowne Medical Office Building, Chapel Hill, North Carolina
Conditions: COPD
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
Recruiting
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
Gender:
All
Ages:
40 years and above
Trial Updated:
02/06/2023
Locations: Chiesi Clinical Trial Site 840215, Charlotte, North Carolina +8 locations
Conditions: COPD, COPD Exacerbation